Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine, Cytarabine, Sorafenib, and Decitabine in Pediatric Relapsed/Refractory Acute Leukemias
NCT06474663Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of cladribine, cytarabine, sorafenib and decitabine in acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL) and acute leukemia of ambiguous lineage (ALAL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Planned start Jul 2025; status: withdrawn.
02
Drugs
cladribinecytarabinesorafenibdecitabine
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT06474663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474663.